Soleno Therapeutics Q4 2025 Earnings Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy SLNO?
Source: seekingalpha
- Strong Financial Performance: Soleno Therapeutics reported a net revenue of $91.7 million for Q4 2025, reflecting a nearly 40% increase from $66 million in Q3, with a full-year net revenue of $190.4 million, indicating a significant enhancement in profitability.
- Sustained Patient Growth: By year-end 2025, the number of active patients using VYKAT XR rose from 764 in Q3 to 859, with 136 new prescribers added, bringing the total to 630, demonstrating strong market penetration momentum.
- Robust Cash Flow: The company generated $48.7 million in cash from operating activities in Q4, ending the year with over $506 million in cash, cash equivalents, and marketable securities, ensuring financial support for future business expansion.
- Optimistic Market Outlook: Management anticipates capturing approximately 1,000 new patient start forms in the next 9 to 12 months and is actively preparing for EU regulatory approval expected in mid-2026, highlighting a strategic focus on international markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 39.060
Low
75.00
Averages
110.50
High
125.00
Current: 39.060
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aardvark Pauses PWS Trial, Shares Plunge 53%
- Trial Pause Reason: Aardvark Therapeutics announced a voluntary pause of its ARD-101 trial for Prader-Willi Syndrome due to cardiac observations in a healthy volunteer study, with data release now expected to be delayed until Q3 2026, potentially impacting the company's future R&D trajectory.
- Severe Market Reaction: Following the trial pause announcement, Aardvark's shares plunged 53% in after-hours trading, reflecting extreme investor concern over the company's outlook, which may lead to financing challenges and diminished market confidence.
- Competitor Dynamics: In contrast, Soleno Therapeutics' VYKAT XR has become the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome, despite facing short-selling pressure and safety concerns from Scorpion Capital, highlighting the intense competition in the market.
- Industry-Wide Challenges: Against the backdrop of Aardvark's trial pause, Acadia Pharmaceuticals also halted development of its intranasal Carbetocin, indicating that the challenges and risks associated with successful R&D in the Prader-Willi Syndrome treatment space are increasing, which could affect the overall investment attractiveness of the sector.
See More
Soleno Therapeutics Appoints New CFO
- Executive Change: Soleno Therapeutics announced the appointment of Jennifer Fulk as CFO, succeeding James Mackaness, who will retire by the end of Q1 and serve as a consultant to ensure a smooth transition.
- Experienced Leadership: Fulk brings over 20 years of experience in public company financial strategy, investor relations, financial reporting, and operational efficiency, including 15 years at Eli Lilly, which is expected to provide Soleno with fresh insights and expertise.
- Market Reaction: Following the announcement, Soleno Therapeutics' stock rose 1.19% in premarket trading to $41.5, indicating investor confidence in the new CFO.
- Future Outlook: Soleno aims to initiate 1,000 new VYKAT XR patient start forms in the next 9-12 months while expanding into new rare disease indications, reflecting the company's proactive strategy for growth and innovation.
See More
Soleno Therapeutics Q4 2025 Earnings Highlights
- Strong Financial Performance: Soleno Therapeutics reported a net revenue of $91.7 million for Q4 2025, reflecting a nearly 40% increase from $66 million in Q3, with a full-year net revenue of $190.4 million, indicating a significant enhancement in profitability.
- Sustained Patient Growth: By year-end 2025, the number of active patients using VYKAT XR rose from 764 in Q3 to 859, with 136 new prescribers added, bringing the total to 630, demonstrating strong market penetration momentum.
- Robust Cash Flow: The company generated $48.7 million in cash from operating activities in Q4, ending the year with over $506 million in cash, cash equivalents, and marketable securities, ensuring financial support for future business expansion.
- Optimistic Market Outlook: Management anticipates capturing approximately 1,000 new patient start forms in the next 9 to 12 months and is actively preparing for EU regulatory approval expected in mid-2026, highlighting a strategic focus on international markets.
See More
Soleno Therapeutics Q4 Earnings Beat Expectations
- Earnings Beat: Soleno Therapeutics reported a Q4 GAAP EPS of $0.80, exceeding expectations by $0.09, indicating a sustained improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $91.73 million, surpassing forecasts by $3.18 million, reflecting strong market demand for its products, which may drive future growth potential.
- Positive Market Reaction: The earnings report's outperformance is likely to positively impact Soleno's stock price, attracting more investor attention and enhancing market expectations for its future performance.
- Strong Financial Health: Continued profitability and revenue growth suggest that Soleno Therapeutics maintains a robust financial position, providing ample funding for future R&D and market expansion efforts.
See More
Soleno Therapeutics to Announce Q4 Earnings on February 25
- Earnings Announcement Date: Soleno Therapeutics is set to release its Q4 earnings on February 25 after market close, with increasing market attention likely impacting its stock price.
- EPS Expectations: Analysts forecast an EPS of $0.71, representing a remarkable 155.9% year-over-year increase, indicating strong performance and improved profitability for the company.
- Revenue Projections: The consensus revenue estimate stands at $88.55 million, reflecting positive advancements in product sales and market expansion, which may bolster investor confidence.
- Historical Financial Data: Historical earnings data for Soleno Therapeutics provides crucial insights for investors, aiding in the assessment of the company's long-term growth potential and market competitiveness.
See More
RBC Initiates Coverage on Rhythm Pharmaceuticals with Outperform Rating
- Market Opportunity Analysis: RBC Capital Markets highlighted that Rhythm Pharmaceuticals' successful Phase 3 trial in 2025 led to a market cap increase of approximately $3.5 billion, showcasing its potential in the rare genetic obesity market.
- Clinical Trial Results: In April 2025, the results from the TRANSCEND trial revealed that setmelanotide achieved a statistically significant 19.8% reduction in BMI among adult and pediatric patients, indicating its effectiveness in treating hypothalamic obesity.
- Sales Growth Expectations: In Q3, Imcivree's sales reached $51.3 million, with analysts projecting that by 2030, revenue could exceed $2 billion as the market for HO patients expands, reflecting strong market demand.
- FDA Review Progress: The FDA extended the review period for setmelanotide by three months to March 20, 2026, and analysts believe Rhythm is well-positioned for future growth, particularly with its development for Prader-Willi syndrome.
See More
Aardvark Pauses PWS Trial, Shares Plunge 53%
- Trial Pause Reason: Aardvark Therapeutics announced a voluntary pause of its ARD-101 trial for Prader-Willi Syndrome due to cardiac observations in a healthy volunteer study, with data release now expected to be delayed until Q3 2026, potentially impacting the company's future R&D trajectory.
- Severe Market Reaction: Following the trial pause announcement, Aardvark's shares plunged 53% in after-hours trading, reflecting extreme investor concern over the company's outlook, which may lead to financing challenges and diminished market confidence.
- Competitor Dynamics: In contrast, Soleno Therapeutics' VYKAT XR has become the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome, despite facing short-selling pressure and safety concerns from Scorpion Capital, highlighting the intense competition in the market.
- Industry-Wide Challenges: Against the backdrop of Aardvark's trial pause, Acadia Pharmaceuticals also halted development of its intranasal Carbetocin, indicating that the challenges and risks associated with successful R&D in the Prader-Willi Syndrome treatment space are increasing, which could affect the overall investment attractiveness of the sector.
See More
Soleno Therapeutics Appoints New CFO
- Executive Change: Soleno Therapeutics announced the appointment of Jennifer Fulk as CFO, succeeding James Mackaness, who will retire by the end of Q1 and serve as a consultant to ensure a smooth transition.
- Experienced Leadership: Fulk brings over 20 years of experience in public company financial strategy, investor relations, financial reporting, and operational efficiency, including 15 years at Eli Lilly, which is expected to provide Soleno with fresh insights and expertise.
- Market Reaction: Following the announcement, Soleno Therapeutics' stock rose 1.19% in premarket trading to $41.5, indicating investor confidence in the new CFO.
- Future Outlook: Soleno aims to initiate 1,000 new VYKAT XR patient start forms in the next 9-12 months while expanding into new rare disease indications, reflecting the company's proactive strategy for growth and innovation.
See More
Soleno Therapeutics Q4 2025 Earnings Highlights
- Strong Financial Performance: Soleno Therapeutics reported a net revenue of $91.7 million for Q4 2025, reflecting a nearly 40% increase from $66 million in Q3, with a full-year net revenue of $190.4 million, indicating a significant enhancement in profitability.
- Sustained Patient Growth: By year-end 2025, the number of active patients using VYKAT XR rose from 764 in Q3 to 859, with 136 new prescribers added, bringing the total to 630, demonstrating strong market penetration momentum.
- Robust Cash Flow: The company generated $48.7 million in cash from operating activities in Q4, ending the year with over $506 million in cash, cash equivalents, and marketable securities, ensuring financial support for future business expansion.
- Optimistic Market Outlook: Management anticipates capturing approximately 1,000 new patient start forms in the next 9 to 12 months and is actively preparing for EU regulatory approval expected in mid-2026, highlighting a strategic focus on international markets.
See More
Soleno Therapeutics Q4 Earnings Beat Expectations
- Earnings Beat: Soleno Therapeutics reported a Q4 GAAP EPS of $0.80, exceeding expectations by $0.09, indicating a sustained improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q4 revenue of $91.73 million, surpassing forecasts by $3.18 million, reflecting strong market demand for its products, which may drive future growth potential.
- Positive Market Reaction: The earnings report's outperformance is likely to positively impact Soleno's stock price, attracting more investor attention and enhancing market expectations for its future performance.
- Strong Financial Health: Continued profitability and revenue growth suggest that Soleno Therapeutics maintains a robust financial position, providing ample funding for future R&D and market expansion efforts.
See More
Soleno Therapeutics to Announce Q4 Earnings on February 25
- Earnings Announcement Date: Soleno Therapeutics is set to release its Q4 earnings on February 25 after market close, with increasing market attention likely impacting its stock price.
- EPS Expectations: Analysts forecast an EPS of $0.71, representing a remarkable 155.9% year-over-year increase, indicating strong performance and improved profitability for the company.
- Revenue Projections: The consensus revenue estimate stands at $88.55 million, reflecting positive advancements in product sales and market expansion, which may bolster investor confidence.
- Historical Financial Data: Historical earnings data for Soleno Therapeutics provides crucial insights for investors, aiding in the assessment of the company's long-term growth potential and market competitiveness.
See More
RBC Initiates Coverage on Rhythm Pharmaceuticals with Outperform Rating
- Market Opportunity Analysis: RBC Capital Markets highlighted that Rhythm Pharmaceuticals' successful Phase 3 trial in 2025 led to a market cap increase of approximately $3.5 billion, showcasing its potential in the rare genetic obesity market.
- Clinical Trial Results: In April 2025, the results from the TRANSCEND trial revealed that setmelanotide achieved a statistically significant 19.8% reduction in BMI among adult and pediatric patients, indicating its effectiveness in treating hypothalamic obesity.
- Sales Growth Expectations: In Q3, Imcivree's sales reached $51.3 million, with analysts projecting that by 2030, revenue could exceed $2 billion as the market for HO patients expands, reflecting strong market demand.
- FDA Review Progress: The FDA extended the review period for setmelanotide by three months to March 20, 2026, and analysts believe Rhythm is well-positioned for future growth, particularly with its development for Prader-Willi syndrome.
See More
